PMC7534527_01
Oral glucose tolerance tests at 2 mo of age (A), at 4 mo of age (B), at the time of
recurrence (C), and 6 mo after the initiation of metformin treatment (D). Circles and
triangles indicate glucose and insulin, respectively.
cpe-29-179-g001.jpg
PMC7534527_02_cpe-29-179-g001.jpg
fig_001
OGTT indicated DM with elevated insulin levels (Fig. 1C). During this period, HOMA-IR scores dropped to 1.6, and OGTT showed relatively improved glycemic control and slightly reduced insulin levels despite the pattern of DM (Fig. 1D).
PMC7534527_02
Oral glucose tolerance tests at 2 mo of age (A), at 4 mo of age (B), at the time of
recurrence (C), and 6 mo after the initiation of metformin treatment (D). Circles and
triangles indicate glucose and insulin, respectively.
cpe-29-179-g001.jpg
PMC7534527_02_cpe-29-179-g001.jpg
fig_001
OGTT indicated DM with elevated insulin levels (Fig. 1C). During this period, HOMA-IR scores dropped to 1.6, and OGTT showed relatively improved glycemic control and slightly reduced insulin levels despite the pattern of DM (Fig. 1D).
Continuous glucose monitoring before metformin treatment (A) and 10 mo after the
initiation of metformin treatment (B).
cpe-29-179-g002.jpg
PMC7534527_02_cpe-29-179-g002.jpg
fig_002
Continuous glucose monitoring (CGM) detected hyperglycemia throughout the day (Fig. 2A). CGM showed a significant reduction in time above the range of glucose level (Fig. 2B).
HbA1c levels after the initiation of metformin treatment. The solid bar at the top
indicates the duration and dosage of treatment.
cpe-29-179-g003.jpg
PMC7534527_02_cpe-29-179-g003.jpg
fig_003
Her HbA1c levels dropped by 0.5-1.0% and remained below 7.0% for more than 12 mo (Fig. 3).